amenamevir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals | 5266 | 841301-32-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Amenamevir is an anti-herpes virus agent for the treatment of herpes zoster (shingles) with a novel mechanism of action. Amenamevir has been observed to inhibit the proliferation of the varicella-zoster virus by inhibiting the activity of the helicase-primase complex, which is essential for viral DNA replication.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.40 | g | O |
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 3, 2017 | PMDA | Maruho |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AX26 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Other antivirals |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Herpes zoster | indication | 4740000 | DOID:8536 |
| Recurrent herpes simplex | indication | 37323009 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.0 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 94X46KW4AE | UNII |
| C2983876 | UMLSCUI |
| CHEMBL4297592 | ChEMBL_ID |
| 11397521 | PUBCHEM_CID |
| DB11701 | DRUGBANK_ID |
| D10564 | KEGG_DRUG |
| 9054 | INN_ID |
| C568714 | MESH_SUPPLEMENTAL_RECORD_UI |
Pharmaceutical products:
None